N2OFF, Inc. (NXTS)
N2OFF, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
N2OFF, Inc. (NXTS) is a Biotechnology company based in IL with a market capitalization of $333.3K. Free cash flow was negative at -$3.8M. This page tracks NXTS's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
IL · 5 employees · IPO Feb 26, 2026
Valuation
Valuation & price
$4.46as of May 17, 2026
—
P/E ratio
Latest-FY diluted EPS
0.07
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Fundamentals
Key fundamentals
$333.3K
Market cap
—
Revenue growth (YoY)
15.7%
Gross margin
-$3.8M
Free cash flow (USD)
-$3.1M
Net debt
Net cash position
-3.1%
Share dilution
2/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2024
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 14, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 8-K eventJun 22, 2026Filing
Securities Purchase Agreement
- 8-K eventJun 12, 2026Filing
Securities Purchase Agreement
- 8-K eventMay 27, 2026Filing
Debt Refinancing
- Quarterly reportMay 14, 2026Filing
10-Q Filed
- 8-K eventApr 30, 2026Filing
Special Meeting Results
- FinancingApr 16, 2026Filing
Securities Registration
- 8-K eventApr 6, 2026Filing
Reverse Stock Split
- Annual reportMar 31, 2026Filing
10-K Filed
Questions
Frequently asked questions
What is N2OFF, Inc.'s market cap?
N2OFF, Inc. (NXTS) has a market capitalization of $333.3K.
What is NXTS's P/E ratio?
A meaningful P/E ratio is not available for NXTS — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is NXTS's price-to-book (P/B) ratio?
NXTS trades at 0.07 times book value per share.
Are insiders buying NXTS stock?
SEC Form 4 filings show no open-market insider buys at N2OFF, Inc. in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.